Clopidogrel
Product Images NDC 31722-902

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 31722-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel300mg30s (Clopidogrel300mg30s)

Label for Clopidogrel Tablets, USP 300 mg by Camber Pharmaceuticals, Inc. The label states the active ingredient as clopidogrel bisulfate USP 391.5 mg equivalent to 300 mg clopidogrel base per tablet. It includes dosage storage instructions, a barcode, and contact information, with a package count of 30 tablets. The label emphasizes dispensing a medication guide to patients and marks the product as Rx only.*

FDA Label Image

Clopidogrel30s75mg (Clopidogrel30s75mg)

Label for Clopidogrel Tablets, USP 75 mg by Camber Pharmaceuticals, Inc., containing 30 tablets. The label includes the NDC number 31722-901-30, storage instructions, and manufacturer information for Camber Pharmaceuticals, Inc. and ScieGen Pharmaceuticals, Inc. Barcode and lot/expiration placeholders are also present.*

FDA Label Image

Clopidogrelfigure2 (Clopidogrelfigure2)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' comparing cumulative event rates over 12 months of follow-up between placebo (plus aspirin) and clopidogrel (plus aspirin). The graph shows lower event rates for the clopidogrel group, with a p-value of 0.00009 indicated. Additional note mentions use of other standard therapies as appropriate.*

FDA Label Image

Clopidogrelfigure6 (Clopidogrelfigure6)

A forest plot chart showing odds ratios with 99% confidence intervals for subgroups in a clopidogrel versus placebo study. Subgroups are categorized by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, with a summary overall effect at the bottom.*

FDA Label Image

Clopidogrelfigure8 (Clopidogrelfigure8)

A hazard ratio plot comparing Clopidogrel and Aspirin across different qualifying conditions (Stroke, MI, PAD) and overall. The x-axis represents the hazard ratio with confidence intervals, and the graph visually indicates which treatment is favored for each condition.*

FDA Label Image

Clopidogrelfigure3 (Clopidogrelfigure3)

A forest plot depicting hazard ratios with 95% confidence intervals for patient baseline characteristics and on-study concomitant medications/interventions from the CURE study. Subgroups include age, gender, race, diabetes, and medication use such as heparin/LMWH, aspirin, GP IIb/IIIa antagonists, beta-blockers, and ACE inhibitors, comparing clopidogrel versus placebo. Hazard ratios are visualized along a central line indicating no effect, with markers showing favorability toward clopidogrel or placebo.*

FDA Label Image

Figure1 (Figure1)

A horizontal error bar chart comparing four proton pump inhibitors: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis ranges approximately from 0.4 to 1.4, with a reference line at 1.0, showing the relative measurement values with confidence intervals for each drug dose.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve chart comparing the percentage of deaths over 28 days between patients treated with clopidogrel and those given a placebo. The x-axis shows days since randomization (up to 28 days), and the y-axis shows the percentage of patients who died before first discharge. The chart indicates a 7% proportional risk reduction for clopidogrel compared to placebo, with 7.5% deaths for clopidogrel and 8.1% for placebo.*

FDA Label Image

Figure5 (Figure5)

A survival curve chart comparing the percentage of patients experiencing death, re-infarction, or stroke before first discharge over a 28-day period. It shows two groups: one treated with clopidogrel and one with placebo. The vertical axis represents the percentage of events, and the horizontal axis represents days since randomization.*

FDA Label Image

Figure8 (Figure8)

Line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up. It compares aspirin and clopidogrel bisulfate, showing slightly lower event rates for clopidogrel bisulfate throughout the period, with a p-value of 0.045 indicating statistical significance.*

FDA Label Image

Structure (Structure)

Chemical structure of clopidogrel bisulfate, showing its molecular arrangement including the thienopyridine core, ester group, and chloride-substituted phenyl ring, accompanied by a bisulfate ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.